BMC Health Services Research

Table 3 Segmented regression analysis for vascular protective medication and comparator coverage 2010 to 2016, EMR cohort

From: Impact of the diabetes Canada guideline dissemination strategy on dispensed vascular protective medications for older patients in Ontario, Canada: a linked EMR and administrative data study

Statin
Variable	Estimate	SE	Pvalue
Baseline prescription rate	63.26	0.52	<.0001
Pre-intervention slope	0.11	0.06	0.11
Change at guideline (2013Q2)	− 0.90	0.61	0.15
Slope change	−0.03	0.09	0.70
ACEi or ARB
Baseline prescription rate	63.99	0.43	<.0001
Pre-intervention slope	−0.15	0.05	0.01
Change at guideline (2013Q2)	−0.46	0.51	0.38
Slope change	0.03	0.07	0.64
Antiplatelet
Baseline prescription rate	9.54	0.15	<.0001
Pre-intervention slope	−0.12	0.02	<.0001
Change at guideline (2013Q2)	0.13	0.17	0.5
Slope change	0.001	0.03	0.97
PPI
Baseline prescription rate	21.84	0.44	<.0001
Pre-intervention slope	0.23	0.05	<.0001
Change at guideline (2013Q2)	0.27	0.43	0.54
Slope change	−0.07	0.08	0.36

SE standard error
ACEi angiotensin-converting enzyme inhibitor; ARB angiotensin receptor blockers; PPI proton pump inhibitor

Back to article page

ISSN: 1472-6963

Contact us

General enquiries: journalsubmissions@springernature.com